Everence Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Everence Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.74M	Buy	2,252 +490	+28%	+$375K	0.11%	160
2025 Q4	$1.36M	Buy	1,762 +407	+30%	+$276K	0.08%	197
2025 Q3	$762K	Sell	1,355 -1,675	-55%	-$947K	0.05%	289
2025 Q2	$1.59M	Sell	3,030 -471	-13%	-$263K	0.1%	169
2025 Q1	$2.22M	Sell	3,501 -330	-9%	-$227K	0.15%	123
2024 Q4	$2.73M	Buy	3,831 +90	+2%	+$75.5K	0.18%	96
2024 Q3	$3.93M	Hold	3,741	–	–	0.25%	71
2024 Q2	$3.33K	Hold	3,741	–	–	0.23%	80
2024 Q1	$3.6K	Hold	3,741	–	–	0.24%	83
2023 Q4	$3.29M	Buy	3,741 +70	+2%	+$57.6K	0.23%	85
2023 Q3	$3.02K	Hold	3,671	–	–	0.23%	84
2023 Q2	$2.7M	Hold	3,671	–	–	0.22%	88
2023 Q1	$3.02K	Hold	3,671	–	–	0.25%	78
2022 Q4	$2.65K	Hold	3,671	–	–	0.23%	91
2022 Q3	$2.53M	Buy	3,671 +570	+18%	+$359K	0.23%	78
2022 Q2	$1.83M	Hold	3,101	–	–	0.16%	116
2022 Q1	$2.17M	Hold	3,101	–	–	0.17%	118
2021 Q4	$1.96M	Buy	3,101 +600	+24%	+$369K	0.15%	125
2021 Q3	$1.51M	Hold	2,501	–	–	0.12%	142
2021 Q2	$1.4M	Hold	2,501	–	–	0.11%	151
2021 Q1	$1.18M	Hold	2,501	–	–	0.11%	161
2020 Q4	$1.21M	Buy	2,501 +260	+12%	+$140K	0.12%	142
2020 Q3	$1.25M	Buy	2,241 +20	+0.9%	+$12.1K	0.14%	129
2020 Q2	$1.36M	Hold	2,221	–	–	0.16%	111
2020 Q1	$1.08M	Hold	2,221	–	–	0.15%	119
2019 Q4	$834K	Buy	2,221 +660	+42%	+$222K	0.12%	172
2019 Q3	$433K	Hold	1,561	–	–	0.07%	308
2019 Q2	$489K	Hold	1,561	–	–	0.08%	265
2019 Q1	$641K	Sell	1,561 -176	-10%	-$72.5K	0.11%	193
2018 Q4	$649K	Hold	1,737	–	–	0.15%	164
2018 Q3	$702K	Hold	1,737	–	–	0.14%	180
2018 Q2	$599K	Hold	1,737	–	–	0.13%	197
2018 Q1	$598K	Hold	1,737	–	–	0.13%	193
2017 Q4	$653K	Hold	1,737	–	–	0.14%	176
2017 Q3	$777K	Buy	1,737 +510	+42%	+$243K	0.18%	157
2017 Q2	$603K	Hold	1,227	–	–	0.15%	185
2017 Q1	$475K	Hold	1,227	–	–	0.12%	210
2016 Q4	$450K	Sell	1,227 -535	-30%	-$203K	0.13%	202
2016 Q3	$708K	Hold	1,762	–	–	0.21%	139
2016 Q2	$615K	Hold	1,762	–	–	0.19%	152
2016 Q1	$635K	Hold	1,762	–	–	0.2%	149
2015 Q4	$957K	Buy	1,762 +322	+22%	+$174K	0.31%	93
2015 Q3	$670K	Hold	1,440	–	–	0.23%	132
2015 Q2	$735K	Hold	1,440	–	–	0.24%	132
2015 Q1	$596K	Hold	1,440	–	–	0.2%	153
2014 Q4	$591K	Buy	+1,440	New	+$566K	0.2%	151

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Everence Capital Management's REGN Position: Q1 2026 in Review

Everence Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 28% in Q1 2026, buying an estimated $375K and bringing the position to 2,252 shares worth $1.74M. The position accounts for 0.11% of the portfolio, ranked #160.

Everence Capital Management first reported a position in REGN in Q4 2014 and has held it in 46 quarters since. The position peaked at $3.93M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Everence Capital Management held 2,252 shares of Regeneron Pharmaceuticals worth $1.74M as of Q1 2026.
Everence Capital Management bought 490 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $375K.
Regeneron Pharmaceuticals made up 0.11% of Everence Capital Management's portfolio in Q1 2026, its #160 holding.
Everence Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
Everence Capital Management's Regeneron Pharmaceuticals position peaked at $3.93M in Q3 2024.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.